Coronavirus (COVID-19) Update - We are open with your safety in mind.
Click here to learn more.
The goal of this study is to evaluate the efficacy and safety of baricitinib 1-mg daily and 2-mg daily in comparison to placebo in adult patients with moderate to severe atopic dermatitis. The study is divided into 3 periods: a 5-week Screening Period, a 104-week Double-Blinded Treatment Period, and a 4-week Post-Treatment Follow-Up Period.
Eli Lilly and Company
Dr. Maria Sotomayor, MD/Dermatology